Work

A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-146079

Authors: Marina Konopleva, Danielle M. Brander, Krish Patel, Catherine S. Diefenbach, Yesid Alvarado, Olga Frankfurt, Monzr M. Al Malki, Alexey V. Danilov, Sameem Abedin, Kebede H. Begna, Avyakta Kallam, Richard G. Ghalie, Matthew S. Davids

Institutions: The University of Texas MD Anderson Cancer Center, Duke Medical Center, Duke Cancer Institute, New York University, Northwestern University, City Of Hope National Medical Center, City of Hope, Medical College of Wisconsin, Mayo Clinic, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, MEI Pharma (United States), Dana-Farber Cancer Institute

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3214513383

Cites:

Cited by: 4

Related to: 10